يعرض 1 - 10 نتائج من 273 نتيجة بحث عن '"Nooka A"', وقت الاستعلام: 1.61s تنقيح النتائج
  1. 1
    Selinexor for the treatment of patients with previously treated multiple myeloma

    المؤلفون: Paul G. Richardson, David A. Siegel, Noa Biran, Ajai Chari, Nizar J. Bahlis, Sundar Jagannath, Cristina Gasparetto, Clifton C. Mo, Sagar Lonial, Ajay K. Nooka

    المصدر: Expert Review of Hematology. 14:697-706

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Receptors, Cytoplasmic and Nuclear, Disease, Karyopherins, Unmet needs, 03 medical and health sciences, Tumor suppressor proteins, 0302 clinical medicine, Internal medicine, medicine, Hematologic malignancy, Humans, Malignant cells, Multiple myeloma, Oncogene, business.industry, Hematology, Triazoles, medicine.disease, Hydrazines, 030220 oncology & carcinogenesis, Multiple Myeloma, Previously treated, business, 030215 immunology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7621fed707615d770c4cec1908b3ea4d
    https://doi.org/10.1080/17474086.2021.1923473

    PDF full text from Publisher
    أضف إلى المفضلة
  2. 2
    Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study

    المؤلفون: Hans C. Lee, Ashraf Badros, Attaya Suvannasankha, Peter M. Voorhees, Joanna Opalinska, Suzanne Trudel, Ajai Chari, Katja Weisel, Sagar Lonial, Al-Ola Abdallah, Lynsey Womersley, Trisha Piontek, Adam D. Cohen, Eric Lewis, Natalie S. Callander, January Baron, Ajay K. Nooka, Ira Gupta, Douglas W. Sborov

    المصدر: Cancer

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Population, Antibodies, Monoclonal, Humanized, Discipline, Refractory, Internal medicine, medicine, Humans, In patient, Single agent, Clinical Trials, education, B‐cell maturation antigen, Multiple myeloma, Very Good Partial Response, education.field_of_study, business.industry, Refractory Multiple Myeloma, Original Articles, medicine.disease, Confidence interval, Progression-Free Survival, multiple myeloma, clinical activity, Oncology, monoclonal antibody, Original Article, business, antibody‐drug conjugate, Follow-Up Studies

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99638554f993323b2882a9adbfbaf6c4
    http://europepmc.org/articles/PMC8597112

    View record at Wiley
    أضف إلى المفضلة
  3. 3
    Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

    المؤلفون: Maria-Victoria Mateos, Mihaela Obreja, Kihyun Kim, Anita Zahlten-Kumeli, Ajay K. Nooka, Andrew Spencer, Katja Weisel, Olga Samoylova, Sebastian Grosicki, Sosana Delimpasi, Kenshi Suzuki, Christopher P. Venner, Thierry Facon, Saad Z. Usmani, Hang Quach

    المصدر: British Journal of Haematology. 194:784-788

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Hematology, Bortezomib, business.industry, Cancer, Daratumumab, medicine.disease, Carfilzomib, chemistry.chemical_compound, chemistry, Internal medicine, medicine, business, Dexamethasone, Multiple myeloma, medicine.drug, Lenalidomide

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a6cb425c4c354bcb59de8b45ea093567
    https://doi.org/10.1111/bjh.17541

    View record at Wiley
    أضف إلى المفضلة
  4. 4
    Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial

    المؤلفون: Lisette Stork-Sloots, David S. Siegel, Martin H. van Vliet, David H. Vesole, Cara A. Rosenbaum, Femke A. de Snoo, Ajay K. Nooka, Durga Prasad Dash, Adriana C Rossi, Ruben Niesvizky, Parameswaran Hari, Cesar Rodriguez, Sena Zümrütçü, Frits van Rhee, Suzanne Lentzsch, Pritish K. Bhattacharyya, Binod Dhakal, Saad Z. Usmani, Divaya Bhutani, Noa Biran

    المصدر: eJHaem. 2:375-384

    مصطلحات موضوعية: Clinical trial, Gene expression profiling, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Gene expression, medicine, Treatment decision making, Newly diagnosed, business, medicine.disease, Multiple myeloma

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d420bd8ecc2f1f77b2ca569f92685dbb
    https://doi.org/10.1002/jha2.209

    View record at Wiley Find this article in full text from ProQuest
    أضف إلى المفضلة
  5. 5
    Maintenance Strategies for Myeloma

    المؤلفون: Ajay K. Nooka, Nisha Joseph

    المصدر: The Cancer Journal. 27:231-238

    مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, Yield (finance), MEDLINE, Newly diagnosed, Disease, Optimal management, Maintenance Chemotherapy, law.invention, Survival benefit, Oncology, Randomized controlled trial, law, medicine, Humans, Prospective Studies, Multiple Myeloma, Prospective cohort study, Intensive care medicine, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc44ee2810dd2ef3477cc9b76fbe6b7f
    https://doi.org/10.1097/ppo.0000000000000524

    أضف إلى المفضلة
  6. 6
    Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

    المؤلفون: Simona Degli Esposti, Andrzej Jakubowiak, Ajay K. Nooka, Natalie S. Callander, Douglas W. Sborov, Asim V. Farooq, Sagar Lonial, Praneetha Thulasi, Julie Byrne, Ashraf Badros, Kathryn Colby, Reza Dana, Ira Gupta, Joanna Opalinska, Rakesh Popat, Heather A. Potter, Brian Zaugg, Trisha Piontek, Bennie H. Jeng, January Baron

    المصدر: Blood Cancer Journal, Vol 11, Iss 5, Pp 1-11 (2021)
    Blood Cancer Journal

    مصطلحات موضوعية: medicine.medical_specialty, Visual acuity, genetic structures, Eye care, Antibodies, Monoclonal, Humanized, Article, Corneal Diseases, Cornea, Antineoplastic Agents, Immunological, Superficial punctate keratopathy, Internal medicine, Medicine, Humans, In patient, Hematologist, Intensive care medicine, RC254-282, Cancer, Patient Care Team, Haematological cancer, Hematology, medicine.diagnostic_test, business.industry, Disease Management, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Refractory Multiple Myeloma, eye diseases, Oncology, Eye examination, sense organs, medicine.symptom, Neoplasm Recurrence, Local, business, Multiple Myeloma

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa8f75c6ed9c4ec8ae621142d8e7fd9
    https://doaj.org/article/f4fbded7918448a587750cd9f85b8f33

    Find this article in full text from ProQuest
    أضف إلى المفضلة
  7. 7
    Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

    المؤلفون: Ting Niu, Steven Sun, Ming Qi, Yafei Wang, Weijun Fu, Jin Lu, Gang An, Xi-Nan Cen, Lijuan Chen, Maria-Victoria Mateos, Ajay K. Nooka, Jianda Hu, Jie Jin, Weiping Liu, Andrew Spencer, Xiao-Jun Huang, Wei Li, Xue Gai, Chengcheng Fu, Zhen Cai, Xue Yang, Katja Weisel, Zheng Ge

    المصدر: Blood. 136:38-41

    مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, Daratumumab, Subgroup analysis, Cell Biology, Hematology, medicine.disease, Biochemistry, Median follow-up, Baseline characteristics, Internal medicine, Medicine, Median body, business, Multiple myeloma, Complete response, Bortezomib/dexamethasone

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7b83f6f9c585b46e89e728562e398783
    https://doi.org/10.1182/blood-2020-136108

    أضف إلى المفضلة
  8. 8
    Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

    المؤلفون: Lotfi Benboubker, Saad Z. Usmani, Shinsuke Iida, Jordan M. Schecter, Maria-Victoria Mateos, Christopher Chiu, Lisa O'Rourke, Ludek Pour, Michele Cavo, Nizar J. Bahlis, Gordon Cook, Jacob P. Laubach, Katja Weisel, Andrew Spencer, Sung-Soo Yoon, Ajay K. Nooka, Meletios A. Dimopoulos, Xiang Qin, Jon Ukropec

    المساهمون: Mateos, Maria-Victoria, Spencer, Andrew, Nooka, Ajay K, Pour, Ludek, Weisel, Katja, Cavo, Michele, Laubach, Jacob P, Cook, Gordon, Iida, Shinsuke, Benboubker, Lotfi, Usmani, Saad Z, Yoon, Sung-Soo, Bahlis, Nizar J, Chiu, Christopher, Ukropec, Jon, Schecter, Jordan M, Qin, Xiang, O'Rourke, Lisa, Dimopoulos, Meletios A

    المصدر: Haematologica

    مصطلحات موضوعية: medicine.medical_specialty, Neutropenia, Gastroenterology, Dexamethasone, Article, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Lenalidomide, Aged, multiple myeloma, Daratumumab, POLLUX, CASTOR, lenalidomide/dexamethasone, bortezomib/dexamethasone, relapsed/refractory multiple myeloma, business.industry, Hazard ratio, Antibodies, Monoclonal, Daratumumab, Hematology, medicine.disease, Confidence interval, 3. Good health, Plasma Cell DIsorders, Multiple Myeloma, business, 030215 immunology, medicine.drug

    وصف الملف: STAMPA

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9db5dfa3798a904c49ea7da607f2926d
    https://doi.org/10.3324/haematol.2019.217448

    أضف إلى المفضلة
  9. 9
    Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

    المؤلفون: Vikas Gupta, Sagar Lonial, Ajay K. Nooka, Lawrence H. Boise, Dhwani Almaula, Leonard T. Heffner, Jonathan L. Kaufman, Madhav V. Dhodapkar, Craig C. Hofmeister, Nisha Joseph

    المصدر: J Clin Oncol

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Bortezomib, Induction chemotherapy, ORIGINAL REPORTS, medicine.disease, Regimen, Internal medicine, medicine, Progression-free survival, business, Survival rate, Dexamethasone, Multiple myeloma, Lenalidomide, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62631ebc48f44086df144d70cd5babc
    https://doi.org/10.1200/jco.19.02515

    أضف إلى المفضلة
  10. 10
    Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

    المؤلفون: Sagar Lonial, Carol Ann Huff, Thaddeus J. Unger, Lingling Li, Sylvain Choquet, Nizar J. Bahlis, Jatin P. Shah, Yi Chai, Cristina Gasparetto, David S. Siegel, Philippe Moreau, Dan T. Vogl, David Dingli, Rafat Abonour, Ajay K. Nooka, Rachid Baz, Donna E. Reece, Mohamad Mohty, Jesus G. Berdeja, Meletios A. Dimopoulos, Sundar Jagannath, Maria Gavriatopoulou, Robert F. Cornell, Michael Kauffman, Andrew Yee, Ajai Chari, Kai Li, Sharon Shacham, Darrell White, Andrzej Jakubowiak, Sascha A. Tuchman, Joshua Richter, Suzanne Lentzsch, Katja Weisel, Christine Chen, Terri L. Parker, Craig C. Hofmeister

    المصدر: Leukemia

    مصطلحات موضوعية: Diarrhea, Male, Cancer Research, medicine.medical_specialty, Loperamide, Nausea, Appetite, Myeloma, Antineoplastic Agents, Neutropenia, Gastroenterology, Bismuth subsalicylate, Article, chemistry.chemical_compound, Internal medicine, medicine, Humans, Adverse effect, Fatigue, Aged, Clinical Trials as Topic, business.industry, Adverse effects, Hematology, Middle Aged, Triazoles, medicine.disease, Thrombocytopenia, Hydrazines, Oncology, chemistry, Megestrol, Vomiting, Female, medicine.symptom, Hyponatremia, business, Multiple Myeloma, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f41e14d803098e3182d3b10be84c44
    http://europepmc.org/articles/PMC7449872

    Find this article in full text from ProQuest
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء